Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company that develops and markets treatments for central nervous system disorders. The company is flagged by Cruelty Free Investors for animal exploitation. This catch-all exclusion applies to commercial exploitation of animals not covered by more specific codes, such as animal testing for product development or regulatory compliance.

A review of the company's public SEC filings indicates the use of animal models in its research. For instance, a Form 8-K filing from October 2023 references an "animal seizure model" used to screen compounds as potential therapies for drug-resistant epilepsy. This demonstrates that animal testing is an integral part of Supernus's drug discovery and development process. As a pharmaceutical company with a pipeline of neurological therapies, this reliance on animal testing is standard for the industry but nonetheless constitutes commercial exploitation of animals under the firm's ethical policy.